2024-03-08 2025-03-31 false Capium Accounts Production 1.1 15547843 2024-03-08 2025-03-31 15547843 bus:AbridgedAccounts 2024-03-08 2025-03-31 15547843 bus:FRS102 2024-03-08 2025-03-31 15547843 bus:AuditExempt-NoAccountantsReport 2024-03-08 2025-03-31 15547843 bus:SmallCompaniesRegimeForAccounts 2024-03-08 2025-03-31 15547843 bus:PrivateLimitedCompanyLtd 2024-03-08 2025-03-31 15547843 2024-03-08 2025-03-31 15547843 2025-03-31 15547843 bus:RegisteredOffice 2024-03-08 2025-03-31 15547843 core:WithinOneYear 2025-03-31 15547843 core:AfterOneYear 2025-03-31 15547843 1 2024-03-08 2025-03-31 15547843 bus:Director1 2024-03-08 2025-03-31 15547843 bus:Director1 2025-03-31 15547843 2023-03-08 15547843 bus:LeadAgentIfApplicable 2024-03-08 2025-03-31 15547843 2024-03-07 15547843 bus:OrdinaryShareClass1 2024-03-08 2025-03-31 15547843 bus:OrdinaryShareClass1 2025-03-31 15547843 core:CostValuation core:Non-currentFinancialInstruments 2025-03-31 15547843 core:CostValuation core:Non-currentFinancialInstruments 2024-03-07 15547843 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2025-03-31 15547843 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2025-03-31 15547843 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2025-03-31 15547843 core:Non-currentFinancialInstruments 2025-03-31 15547843 core:Non-currentFinancialInstruments 2024-03-07 15547843 core:ShareCapital 2025-03-31 15547843 core:RetainedEarningsAccumulatedLosses 2025-03-31 15547843 dpl:Item1 2024-03-08 15547843 dpl:Item1 2025-03-31 iso4217:GBP xbrli:shares xbrli:pure
Registered Number: 15547843
England and Wales

 

 

 

REN THERAPEUTICS LTD



Abridged Accounts
 


Period of accounts

Start date: 08 March 2024

End date: 31 March 2025
 
 
Notes
 
2025
£
Current assets    
Cash at bank and in hand 7,993 
Creditors: amount falling due within one year (8,500)
Net current assets (507)
 
Total assets less current liabilities (507)
Net assets (507)
 

Capital and reserves
   
Called up share capital 3 100 
Profit and loss account (607)
Shareholders' funds (507)
 


For the period ended 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:
  1. The members have not required the company to obtain an audit of its accounts for the period in question in accordance with section 476.
  2. The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006, the income statement has not been delivered to the Registrar of Companies.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with section 444(2A).
The financial statements were approved by the director on 04 June 2025 and were signed by:


-------------------------------
Sowmya RENIKINDI
Director
1
General Information
REN THERAPEUTICS LTD is a private company, limited by shares, registered in England and Wales, registration number 15547843, registration address 15 HEATH PARK COURT, ROMFORD ENGLAND, RM2 5UA.

The presentation currency is £ sterling.
1.

Accounting policies

Significant accounting policies
Statement of compliance
These financial statements have been prepared in compliance with FRS 102 – The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.
Basis of preparation
The financial statements have been prepared under the historical cost convention as modified by the revaluation of land and buildings and certain financial instruments measured at fair value in accordance with the accounting policies.
The financial statements are prepared in sterling which is the functional currency of the company.
Going concern basis
The directors believe that the company is experiencing good levels of sales growth and profitability, and that it is well placed to manage its business risks successfully. Accordingly, they have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus they continue to adopt the going concern basis of accounting in preparing the financial statements.
2.

Average number of employees

Average number of employees during the period was 0.
3.

Share Capital

Allotted, called up and fully paid
2025
£
100 Ord shares of £1.00 each 100 
100 

2